Market closed
Arrowhead Pharmaceuticals/$ARWR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Ticker
$ARWR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
609
ISIN
US04280A1007
Website
ARWR Metrics
BasicAdvanced
$1.7B
-
-$5.15
0.96
-
Price and volume
Market cap
$1.7B
Beta
0.96
52-week high
$30.41
52-week low
$9.57
Average daily volume
1.9M
Financial strength
Current ratio
6.085
Quick ratio
5.902
Long term debt to equity
1,540.546
Total debt to equity
1,555.142
Interest coverage (TTM)
-12.87%
Management effectiveness
Return on assets (TTM)
-47.71%
Return on equity (TTM)
-565.33%
Valuation
Price to revenue (TTM)
657.96
Price to book
31.64
Price to tangible book (TTM)
37.43
Price to free cash flow (TTM)
-2.878
Growth
Revenue change (TTM)
-98.62%
Earnings per share change (TTM)
85.93%
3-year revenue growth (CAGR)
-74.13%
3-year earnings per share growth (CAGR)
43.09%
What the Analysts think about ARWR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
ARWR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ARWR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire·1 month ago
Arrowhead Pharmaceuticals Is Finally Arriving
Seeking Alpha·2 months ago
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $1.7B as of May 10, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of May 10, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.